Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Min Xiangmin
AddedMar 31, 2024
UpdatedMay 1, 2026
Min Xiangmin

Min Xiangmin

Co-Founder, Decheng Capital

Min Xiangmin's Career

Decheng Capital
Decheng Capital

Menlo Park, CA, US

Co-Founder
AccuraGen
AccuraGen

Menlo Park, CA, US

Board Member· Board
VelosBio
VelosBio

San Diego, CA, US

Board Member· Board
Genapsys
Genapsys

Redwood City, CA, US

Board Member· Board
GRAIL
GRAIL

Menlo Park, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Min Xiangmin's Career

Decheng Capital
Decheng Capital
Investment FirmInvestment Firm242012Menlo Park, CA, US
Co-Founder

Leadership at Decheng Capital

Min CuiMin CuiCo-Founder
AccuraGen
AccuraGen
Series B$40M192013Menlo Park, CA, US
Board Member· Board

Leadership at AccuraGen

Shengrong LinShengrong LinCo-Founder
Grace ZhaoGrace ZhaoCo-Founder
Ying KangYing KangCEO
Dan ZabrowskiDan ZabrowskiBoard Member
Victor TongVictor TongBoard Member

Similar to AccuraGen

Foundation MedicineFoundation MedicineCambridge, MA, USCancer Diagnosticsest. 2010Foundation MedicineCambridge, MA, US · est. 2010

Foundation Medicine, Inc.: A U.S. genomics firm specializing in personalized cancer diagnostic technology.

Public · $96.5M662
LucenceLucencePalo Alto, CA, USLiquid Biopsyest. 2016LucencePalo Alto, CA, US · est. 2016

Lucence: Precision oncology firm offering ultrasensitive liquid biopsy tests for early cancer detection.

Series A · $29.2M85
Liquid GenomicsLiquid GenomicsTorrance, CA, USCancer Diagnosticsest. 2013Liquid GenomicsTorrance, CA, US · est. 2013

Providing Digital PCR and Allele Specific Blocker PCR for sensitive cancer gene mutation detection.

Seed · $76k4
VelosBio
VelosBio
Acquired$202.7M02017San Diego, CA, US
Board Member· Board

Leadership at VelosBio

Dave JohnsonDave JohnsonFounder & CEO
Jonathan TobinJonathan TobinBoard Member
Mark ChinMark ChinBoard Member

Similar to VelosBio

Kronos BioKronos BioSan Mateo, CA, USCancer Therapiesest. 2017Kronos BioSan Mateo, CA, US · est. 2017

UK-based Kronos Bio, Inc. pioneers in discovering and developing therapies for complex cancer targets globally.

Public · $278M105
Palm TherapeuticsPalm TherapeuticsSan Diego, CA, USCancer Treatmentest. 2018Palm TherapeuticsSan Diego, CA, US · est. 2018

Revolutionizing cancer treatment with next-gen root-level therapeutics.

Angel · $991.1k7
Genapsys
Genapsys

Redwood City, CA, US

Board Member· Board
GRAIL
GRAIL
Public$2B8232016Menlo Park, CA, US
Board Member· Board

Recent news

Littlebird raises $11M for its AI-assisted ‘recall’ tool that reads your computer screenTechCrunch · 2026

Leadership at GRAIL

Mostafa RonaghiMostafa RonaghiBoard Member
Brook ByersBrook ByersBoard Member
Jeff DeanJeff DeanBoard Member
Jeff HuberJeff HuberBoard Member
Bob RagusaBob RagusaCEO
William H. RastetterWilliam H. RastetterBoard Member

Similar to GRAIL

FreenomeFreenomeSouth San Francisco, CA, USCancer Detectionest. 2014FreenomeSouth San Francisco, CA, US · est. 2014

Freenome, a US-based company, is dedicated to providing tools for cancer detection, treatment, and prevention.

Late Stage Private · $1.1B375
Guardant HealthGuardant HealthPalo Alto, CA, USCancer Diagnosticsest. 2011Guardant HealthPalo Alto, CA, US · est. 2011

Guardant Health: A Palo Alto-based biotech firm providing global cancer diagnostics and sequencing services.

Public1.8k
Exact SciencesExact SciencesMadison, WI, USCancer Diagnosticsest. 1995Exact SciencesMadison, WI, US · est. 1995

Exact Sciences Corp., a US-based firm, develops non-invasive tests for early colorectal cancer detection.

Public · $2.1B6.4k

Min Xiangmin's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakChi-hyung SongChi-hyung SongBoard Member · DunamuHaeil YiHaeil YiCo-Founder · DunamuHyoung-nyon KimHyoung-nyon KimCo-Founder · Dunamu

People Similar to Min Xiangmin

Ning MaNing MaBoard Member · Bocom International HoldingsXiangwei WengXiangwei WengFounder · Shining CapitalDavid ChenDavid ChenCo-Founder · Huashan CapitalJingwei ZhengJingwei ZhengCo-Founder · Eminence VenturesPei HePei HeCo-Founder · Eminence VenturesJiancong XiaoJiancong XiaoCo-Founder · Everest Venture Capital